Oxethazaine
20 brands · 20 companies · product forms
Opportunity snapshot
Who competes here
Top companies by brand count — fragmented market (no dominant player) · leader share 5%
Price room
max/min price ratio 3.47x across 3 trusted points (Rs 61.04-211.8). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Why this score
Launch attractiveness
40% supply-gap(0) + 25% price-variation(62) + 20% low-competition(49) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.
Market saturation
20 canonical companies and 20 brands compete (saturation pegged at 30 companies / 150 brands).
Price room
max/min price ratio 3.47x across 3 trusted points (Rs 61.04-211.8). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Regulatory risk
No DRAP alerts on this molecule's brands.
Confidence
Reduced by: no ATC code.
Packaged brief for this lower opportunity?
Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.
See packaged reports All 3868 molecules